Spero.jpg
Spero Reports Preliminary Findings from Phase 1 Clinical Trial of SPR206 and Plans to Advance Program with Alliance Partners Everest Medicines and the Department of Defense
January 13, 2020 08:00 ET | Spero Therapeutics, Inc.
CAMBRIDGE, Mass., Jan. 13, 2020 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and...
Spero.jpg
Spero Therapeutics Announces Second Quarter 2019 Operating Results and Provides Pipeline Update
August 08, 2019 16:10 ET | Spero Therapeutics, Inc.
CAMBRIDGE, Mass., Aug. 08, 2019 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq:SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and...
Spero.jpg
Spero Therapeutics Announces $5.9 Million Award from U.S. Department of Defense to Further Clinical Development of SPR206
July 16, 2019 08:00 ET | Spero Therapeutics, Inc.
CAMBRIDGE, Mass., July 16, 2019 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq:SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and...
Spero.jpg
Spero Therapeutics to Present Data for All Pipeline Programs at the ASM Microbe 2019 Conference
June 17, 2019 08:30 ET | Spero Therapeutics, Inc.
CAMBRIDGE, Mass., June 17, 2019 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq:SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and...
Spero.jpg
Spero Therapeutics Announces First Quarter 2019 Operating Results and Provides Pipeline Review
May 09, 2019 16:10 ET | Spero Therapeutics, Inc.
CAMBRIDGE, Mass., May 09, 2019 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq:SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and...
Spero.jpg
Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 01, 2019 08:00 ET | Spero Therapeutics, Inc.
CAMBRIDGE, Mass., May 01, 2019 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq:  SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and...
Spero.jpg
Spero Therapeutics Highlights SPR994 Data at the 29th European Congress of Clinical Microbiology and Infectious Diseases
April 08, 2019 08:30 ET | Spero Therapeutics, Inc.
CAMBRIDGE, Mass., April 08, 2019 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq:SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and...
Spero.jpg
Spero Therapeutics Receives FDA Fast Track Designation for SPR994 for the treatment of Complicated Urinary Tract infections and Acute Pyelonephritis
March 29, 2019 08:00 ET | Spero Therapeutics, Inc.
CAMBRIDGE, Mass., March 29, 2019 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq:SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and...
Spero.jpg
Spero Announces Appointment of Cynthia Smith to its Board of Directors
March 19, 2019 08:00 ET | Spero Therapeutics, Inc.
CAMBRIDGE, Mass., March 19, 2019 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq:SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and...
Spero.jpg
Spero Therapeutics to Present at March Investor Conferences
March 01, 2019 08:30 ET | Spero Therapeutics, Inc.
CAMBRIDGE, Mass., March 01, 2019 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq:SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and...